Updates on the diagnosis, prognosis, and management of IgA vasculitis in adults: A narrative review
Journal of the American Academy of Dermatology · 2026-08 · 95 (2) · 474-484
DOI: 10.1016/j.jaad.2026.02.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Academy of Dermatology, 2026-08. Verfasst von Valerie R Stichert und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Cincinnati College of Medicine, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Immunoglobulin A, IgA Vasculitis, Vasculitis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ohio State University.
Abstract (Originalsprache)
IgA vasculitis (IgAV) is classically associated with children, yet it is not uncommon in adults. Adult IgAV remains difficult to diagnose and manage because most existing criteria and therapeutic recommendations were developed for pediatric populations, leaving uncertainty around how to best diagnose and treat adult patients. To provide clinically useful, evidence-based guidance, we reviewed current literature on adult IgAV, including clinical features, diagnostic approaches, prognostic indicators, treatment strategies, and monitoring recommendations. Compared with pediatric cases, adults generally experience a more severe disease course, with higher rates of renal and gastrointestinal involvement and greater risk of long-term morbidity. Diagnostic evaluation in adults is complicated by the lack of adult-specific diagnostic criteria and variable direct immunofluorescence findings. Prognostic analyses consistently identified renal and gastrointestinal involvement, older age, and medical comorbidities as predictors of adverse outcomes. Treatment evidence remains limited, as randomized controlled trials are lacking. Monitoring recommendations emphasize prolonged renal follow-up, as abnormalities may appear several months after initial presentation. Overall, adult IgAV constitutes a distinct clinical entity with greater severity and management challenges than pediatric disease, underscoring the need for dedicated adult-focused research and the development of standardized diagnostic and treatment guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Cincinnati College of Medicine, Cincinnati, Ohio.
- Ohio University Heritage College of Osteopathic Medicine, Athens, Ohio.
- Wright State University Boonshoft School of Medicine, Fairborn, Ohio.
- Division of Nephrology, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.
- Department of Dermatology, The Ohio State University Wexner Medical Center, Gahanna, Ohio.
- Division of Rheumatology and Immunology, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Förderung
- Ohio State University
Zitieren
APA
Stichert, V. R., Santoso, B., Winters, B. G., Thompson, S., Ayoub, I., Kaffenberger, B. H., Lin, J., Werth, V., & Korman, A. M. (2026). Updates on the diagnosis, prognosis, and management of IgA vasculitis in adults: A narrative review. Journal of the American Academy of Dermatology, 95(2), 474-484. https://doi.org/10.1016/j.jaad.2026.02.007
Vancouver
Stichert VR, Santoso B, Winters BG, Thompson S, Ayoub I, Kaffenberger BH, et al. Updates on the diagnosis, prognosis, and management of IgA vasculitis in adults: A narrative review. Journal of the American Academy of Dermatology. 2026;95(2):474-484. doi:10.1016/j.jaad.2026.02.007
BibTeX
@article{Stichert2026,
author = {Stichert, Valerie R and Santoso, Breanna and Winters, Bethany G and Thompson, Sophia and Ayoub, Isabelle and Kaffenberger, Benjamin H and Lin, Judith and Werth, Victoria and Korman, Abraham M},
title = {Updates on the diagnosis, prognosis, and management of IgA vasculitis in adults: A narrative review},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {2},
pages = {474--484},
doi = {10.1016/j.jaad.2026.02.007}
}
EUVIMED